AXSM - Axsome Therapeutics Inc.

-

$undefined

N/A

(N/A)

Axsome Therapeutics Inc. NasdaqGM:AXSM Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York.

Location: One World Trade Center, New York, NY, 10007, United States | Website: https://www.axsome.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

5.334B

Cash

300.9M

Avg Qtr Burn

-29.58M

Short % of Float

11.29%

Insider Ownership

16.45%

Institutional Own.

80.48%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Sunosi® (solriamfetol) Details
Mental health, Excessive daytime sleepiness

Approved

Quarterly sales

Approved

Quarterly sales

NDA

Submission

AXS-05 Details
Alzheimer's disease

NDA

Submission

NDA

Submission

Solriamfetol Details
Shift work disorder

Phase 3

Data readout

Solriamfetol Details
Binge eating disorder

Phase 3

Data readout

AXS-05 Details
Alzheimer's disease

Phase 3

Data readout

Solriamfetol Details
Attention deficit hyperactivity disorder

Phase 3

Update

Solriamfetol Details
Major depressive disorder

Phase 3

Update

AXS-05 Details
Smoking cessation

Phase 2/3

Initiation